↑ 疾患リストへ ← 戻る

 39. 中毒性表皮壊死症 [臨床試験数:11,薬物数:17(DrugBank:9),標的遺伝子数:10,標的パスウェイ数:18] 

Searched query = "Toxic epidermal necrolysis", "Toxic epidermal necrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02987257December 20202 September 2019Cyclosporine and Etanercept in Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisPhase III Randomized Trial of the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Comparing Supportive Care, Cyclosporine, and Biologic Therapy in AdultsStevens-Johnson Syndrome;Toxic Epidermal NecrolysesDrug: cyclosporin A;Drug: Etanercept 50 MG Solution for Injection;Drug: PlacebosVanderbilt University Medical CenterUniversity of Ottawa;University of Toronto;Loyola University;University of South Florida;University of TexasNot recruiting18 YearsN/AAll267Phase 3United States
2NCT03585946September 1, 201816 July 2018Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal NecrolysisA Prospective Multicenter Cohort Study Assessing Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal NecrolysisStevens-Johnson Syndrome;Toxic Epidermal Necrolysis;Drug ReactionDrug: Site specific standard of care comparisonMassachusetts General HospitalNot recruiting18 YearsN/AAll750N/A
3JPRN-jRCTs06118004401/06/201722 July 2019Multicenter Open-trial of Steroid pulse therapy for SJS/TENMulticenter Open-trial of Steroid pulse therapy for SJS/TEN - MOSST StudyStevens-Johnson syndrome and Toxic epidermal necrolysis1. infusion of methylprednisolone at 500~1000 mg/d
(0.9% N/S in 3 hour) for 3 consecutive days.
2. Oral predonisolone (0.5 mg/kg/d) was initiated on the
day following the last dose of methylprednisolone, and
prednisolone was subsequently tapered within 2 weeks.
If the ocular involvement score is more than 2, dose of
oral predonisolone (1 mg/kg/d) is recommended.
Eishin MoritaRecruiting20 age old90 age oldBoth20Phase 2Taiwan;Germany
4NCT02319616November 201626 August 2019Topical Clobetasol for the Treatment of Toxic Epidermal NecrolysisA Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN)Toxic Epidermal NecrolysisDrug: Clobetasol 0.05% ointment;Drug: PlaceboUniversity of California, DavisNot recruiting7 Years85 YearsAll0Phase 1/Phase 2United States
5NCT02795143November 20169 January 2017Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot StudyEvaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot StudyToxic Epidermal NecrolysisDrug: Isotretinoin;Other: PlaceboMassachusetts General HospitalRecruiting18 Years69 YearsBoth40N/AUnited States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02739295July 20166 May 2019G-CSF in the Treatment of Toxic Epidermal NecrolysisEvaluation of G-CSF as a Treatment of Toxic Epidermal NecrolysisStevens - Johnson SyndromeDrug: recombinant granulocyte - colony stimulating factor;Drug: NaCl 0.9%University Hospital of LiegeRecruiting18 YearsN/AAll10Phase 4Belgium
7NCT02126020November 201416 December 2017Topical Infliximab in Autoimmune Eyes With KeratoprosthesisTopical Infliximab in Autoimmune Eyes With KeratoprosthesisStevens-Johnson Syndrome;Toxic Epidermal Necrolysis (Lyell) Syndrome;Mucous Membrane PemphigoidDrug: topical infliximabJames Chodosh, MD, MPHMassachusetts Eye and Ear Infirmary;Fonds de recherche en ophtalmologie de l'Université de Montréal (FROUM)Not recruiting18 Years80 YearsAll0Phase 1/Phase 2United States;Canada
8NCT01696500October 201219 February 2015Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.Stevens-Johnson Syndrome;Toxic Epidermal NecrolysisDrug: Intravenous immunoglobulinNihon Pharmaceutical Co., LtdNot recruiting20 YearsN/ABoth10Phase 3Japan
9NCT01256489December 201017 November 2015Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal NecrolysisStevens-Johnson Syndrome;Corneal BlindnessDrug: InfliximabMassachusetts Eye and Ear InfirmaryNot recruiting18 YearsN/ABoth0Phase 1/Phase 2United States
10NCT02037347October 201019 October 2017Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal NecrolysisPalifermin Treatment of Toxic Epidermal NecrolysisToxic Epidermal Necrolysis;Stevens-Johnson SyndromeDrug: PaliferminBrett KingSwedish Orphan BiovitrumNot recruiting18 YearsN/AAll1Phase 1/Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00372723July 200619 February 2015Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal NecrolysisToxic Epidermal NecrolysisDrug: Remicaide (infliximab)Loyola UniversityNot recruiting18 YearsN/ABoth0Phase 2United States

先頭へ